Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Johnson & Johnson (NYSE: JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced the submission of a supplemental New Drug Application/sNDA to the US FDA for ...

A 49-study meta-analysis showed that the mean number of discontinuation symptoms 1 week after stopping an antidepressant was ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Neurocrine Biosciences' potential shines with robust assets, strong pipeline, and growth opportunities. Learn more about NBIX ...

SNS Insider Highlights Surging Demand in the U.S. Schizophrenia Drugs Market—Valued at USD 2.84 Billion in 2024—As Second-Generation Antipsychotics and Long-Acting Injectables Drive Nearly 34% ...

The FDA has approved its requested updated versions of expanded warning labels for COVID-19 vaccines. As Healio previously reported, the FDA sent letters to Moderna and Pfizer/BioNTech in April ...

The FDA has approved required updates to the labeling of Pfizer’s Comirnaty and Moderna’s Spikevax COVID-19 vaccines to include revised warnings about the risk of myocarditis and pericarditis ...

For patients with schizophrenia, weekly LYN-005 provides sustained release of risperidone at therapeutic concentrations.

U.S. health officials have expanded warnings about a rare heart side effect associated with the two leading COVID-19 vaccines ...